Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751530 · ClinicalTrials.gov registry record
BRAVO: Background Regimen of Raltegravir on Virologic Outcome
A clinical trial of HIV Infections, sponsored by Community Research Initiative of New England.
- Completed
- Registry status
- 442
- Enrollment target
- 15
- Study locations
NCT00751530: Completed study of HIV Infections, sponsored by Community Research Initiative of New England.
NCT00751530 is a study of HIV Infections that has completed, run by Community Research Initiative of New England. The registered enrollment target is 442 participants, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00751530, a study of HIV Infections, has completed, sponsored by Community Research Initiative of New England.
- COMPLETED
- Registry status
- 442 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.
Primary Outcome
The HIV RNA (viral load) was measured using standard of care testing via local laboratories.
Conditions Studied
Interventions
- DRUG raltegravir
Study Locations (15)
California
- Light Source Medical - Los Angeles
- AIDS Healthcare Foundation - Los Angeles
- Synergy Hematology and Oncology - Los Angeles
- Quest Clinical Research - San Francisco
District of Columbia
- Dupont Circle Physicians Group - Washington D.C.
- Capital Medical Associates PC - Washington D.C.
Massachusetts
- Community Research Initiative - Boston
- Community Research Initiative - West - Springfield
New York
- Infectious Diseases and HIV Medicine Immunodeficiency Clinic - Buffalo
- Bellman, MD - New York
Connecticut
- Connecticut Health Care Group - Glastonbury
Florida
- Orlando Immunology Center - Orlando
Illinois
- Ruth M. Rothstein CORE Center - Chicago
Pennsylvania
- Mounzer, MD - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2008-03-01 |
| Est. Completion | 2009-06-15 |
What the finished NCT00751530 record still lists
NCT00751530 is an observational study that tracks outcomes without assigning an intervention. The registered 442 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which raltegravir is the first listed.
NCT00751530 lists 15 locations in 9 states (California, District of Columbia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00751530 about?
NCT00751530 is a clinical study titled "BRAVO: Background Regimen of Raltegravir on Virologic Outcome". This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.
What is the current status of trial NCT00751530?
This trial is currently completed. The enrollment target is 442 participants. The study started on 2008-03-01. Estimated completion is 2009-06-15.
What conditions does trial NCT00751530 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00751530?
The interventions under investigation include: raltegravir (DRUG).
Who is sponsoring clinical trial NCT00751530?
This trial is sponsored by Community Research Initiative of New England, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00751530 being conducted?
This trial has 15 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00751530's enrollment target sits among peer trials
442 75th of 542 higher than 468 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- NCT06659029 · 442 participants
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI